Share Price and Basic Stock Data
Last Updated: January 2, 2026, 5:14 pm
| PEG Ratio | -1.90 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Chemcrux Enterprises Ltd operates in the specialty chemicals sector, focusing on niche products. The company’s stock price stood at ₹108 with a market capitalization of ₹161 Cr. Over the past fiscal years, revenue trends have shown fluctuations, with sales reported at ₹95.27 Cr in March 2022, marginally declining to ₹95.15 Cr in March 2023, and further projected to drop to ₹78.47 Cr by March 2024. The trailing twelve months (TTM) revenue is recorded at ₹70.69 Cr, indicating a downward trend. Quarterly sales figures also exhibit variability, with the peak reported at ₹27.74 Cr in September 2022, tapering to ₹15.84 Cr by September 2023. The operating profit margin (OPM) fluctuated significantly from 20.91% in September 2022 to 14.77% in September 2023, reflecting challenges in maintaining profitability amid changing market conditions. Overall, the revenue trajectory suggests a need for strategic reassessment to stabilize income streams.
Profitability and Efficiency Metrics
The profitability metrics for Chemcrux Enterprises reveal a mixed performance. The company reported a net profit of ₹14.36 Cr for the fiscal year ending March 2023, which is projected to decline to ₹8.44 Cr in March 2024, and further to ₹4.19 Cr by March 2025. This downward trend is concerning, particularly as the return on equity (ROE) stood at 5.36%, indicating limited returns for shareholders. The return on capital employed (ROCE) also reflects a decline, recorded at 7.11% in March 2025, down from 27.75% in March 2023. The interest coverage ratio, while healthy at 6.14x, shows that the company is capable of meeting its interest obligations, but the declining net profit margin, which fell to 5.58% in March 2025 from 10.76% in March 2024, raises questions about long-term sustainability. Overall, while Chemcrux maintains operational efficiency, its profitability metrics necessitate urgent attention.
Balance Sheet Strength and Financial Ratios
Chemcrux Enterprises’ balance sheet reveals a mix of strengths and weaknesses. The total assets stood at ₹112.15 Cr in March 2025, with total liabilities of ₹112.72 Cr, indicating a precarious position with liabilities slightly outpacing assets. Reserves have grown to ₹62.52 Cr, providing a cushion for financial stability, though borrowings have also increased to ₹23.73 Cr, suggesting a reliance on debt financing. The current ratio, reported at 2.31x, indicates adequate short-term liquidity, while the quick ratio of 1.81x confirms that the company can cover its immediate liabilities without relying on inventory sales. However, the debt-to-equity ratio has risen to 0.55, highlighting increased financial leverage, which may pose risks if cash flows do not improve. Overall, while the company has a solid liquidity position, its reliance on debt financing could become a disadvantage if market conditions worsen.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Chemcrux Enterprises Ltd reflects a strong promoter base, with promoters holding 72.92% of the total shares. This significant ownership indicates a high level of commitment from the founding members, which can instill confidence among investors. The public shareholding stands at 27.07%, with a total of 23,478 shareholders as of September 2025, indicating a broad base of retail investors. However, the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) could signal a lack of confidence from larger institutional players, which may affect the stock’s liquidity and overall market perception. Furthermore, the declining number of shareholders from 30,266 in March 2023 to 23,478 in September 2025 suggests a potential sell-off or lack of interest, which could negatively impact the stock price. Investor confidence appears mixed, influenced by the company’s performance and external market conditions.
Outlook, Risks, and Final Insight
The outlook for Chemcrux Enterprises Ltd appears challenging, primarily due to declining revenues and profitability metrics. The company faces risks from increasing competition in the specialty chemicals sector, potential supply chain disruptions, and rising input costs, which could further erode margins. Additionally, the growing reliance on debt financing could pose liquidity risks if cash flows do not stabilize. However, the strong promoter holding and a substantial reserve base provide some assurance against financial distress. Moving forward, the company must focus on enhancing operational efficiency, diversifying its product portfolio, and exploring new market opportunities to regain investor confidence and stabilize its financial performance. If Chemcrux can successfully navigate these challenges, it may position itself for recovery in a volatile market environment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 392 Cr. | 42.7 | 80.8/40.0 | 24.4 | 20.5 | 0.94 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 31.2 Cr. | 63.5 | 88.8/56.0 | 14.9 | 89.6 | 1.57 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 49.4 Cr. | 726 | 932/600 | 22.8 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,700 Cr. | 81.6 | 111/68.2 | 24.5 | 22.0 | 0.61 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 637 Cr. | 256 | 393/230 | 22.9 | 93.8 | 0.98 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,937.80 Cr | 718.94 | 67.19 | 183.02 | 0.43% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 27.74 | 20.50 | 20.01 | 22.29 | 15.84 | 21.81 | 18.54 | 17.11 | 17.76 | 19.42 | 15.97 | 16.75 | 18.55 |
| Expenses | 21.94 | 15.47 | 14.90 | 18.43 | 13.50 | 17.43 | 15.92 | 15.05 | 15.40 | 16.73 | 14.03 | 15.16 | 16.88 |
| Operating Profit | 5.80 | 5.03 | 5.11 | 3.86 | 2.34 | 4.38 | 2.62 | 2.06 | 2.36 | 2.69 | 1.94 | 1.59 | 1.67 |
| OPM % | 20.91% | 24.54% | 25.54% | 17.32% | 14.77% | 20.08% | 14.13% | 12.04% | 13.29% | 13.85% | 12.15% | 9.49% | 9.00% |
| Other Income | 0.32 | 0.31 | 0.18 | 0.18 | 0.24 | 0.56 | 0.35 | 0.39 | 0.26 | 0.61 | 0.28 | 0.61 | 0.80 |
| Interest | 0.13 | 0.07 | 0.47 | 0.31 | 0.21 | 0.17 | 0.13 | 0.13 | 0.33 | 0.60 | 0.58 | 0.52 | 0.52 |
| Depreciation | 0.48 | 0.54 | 0.58 | 0.57 | 0.58 | 0.58 | 0.55 | 0.56 | 0.73 | 0.92 | 0.91 | 0.95 | 0.96 |
| Profit before tax | 5.51 | 4.73 | 4.24 | 3.16 | 1.79 | 4.19 | 2.29 | 1.76 | 1.56 | 1.78 | 0.73 | 0.73 | 0.99 |
| Tax % | 26.86% | 24.31% | 31.13% | 26.27% | 30.17% | 36.75% | 3.49% | 29.55% | 26.28% | 25.84% | 35.62% | 19.18% | 18.18% |
| Net Profit | 4.03 | 3.58 | 2.92 | 2.33 | 1.24 | 2.66 | 2.21 | 1.24 | 1.15 | 1.33 | 0.47 | 0.58 | 0.80 |
| EPS in Rs | 2.72 | 2.42 | 1.97 | 1.57 | 0.84 | 1.80 | 1.49 | 0.84 | 0.78 | 0.90 | 0.32 | 0.39 | 0.54 |
Last Updated: December 27, 2025, 2:04 pm
Below is a detailed analysis of the quarterly data for Chemcrux Enterprises Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 18.55 Cr.. The value appears strong and on an upward trend. It has increased from 16.75 Cr. (Jun 2025) to 18.55 Cr., marking an increase of 1.80 Cr..
- For Expenses, as of Sep 2025, the value is 16.88 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.16 Cr. (Jun 2025) to 16.88 Cr., marking an increase of 1.72 Cr..
- For Operating Profit, as of Sep 2025, the value is 1.67 Cr.. The value appears strong and on an upward trend. It has increased from 1.59 Cr. (Jun 2025) to 1.67 Cr., marking an increase of 0.08 Cr..
- For OPM %, as of Sep 2025, the value is 9.00%. The value appears to be declining and may need further review. It has decreased from 9.49% (Jun 2025) to 9.00%, marking a decrease of 0.49%.
- For Other Income, as of Sep 2025, the value is 0.80 Cr.. The value appears strong and on an upward trend. It has increased from 0.61 Cr. (Jun 2025) to 0.80 Cr., marking an increase of 0.19 Cr..
- For Interest, as of Sep 2025, the value is 0.52 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.52 Cr..
- For Depreciation, as of Sep 2025, the value is 0.96 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.95 Cr. (Jun 2025) to 0.96 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.99 Cr.. The value appears strong and on an upward trend. It has increased from 0.73 Cr. (Jun 2025) to 0.99 Cr., marking an increase of 0.26 Cr..
- For Tax %, as of Sep 2025, the value is 18.18%. The value appears to be improving (decreasing) as expected. It has decreased from 19.18% (Jun 2025) to 18.18%, marking a decrease of 1.00%.
- For Net Profit, as of Sep 2025, the value is 0.80 Cr.. The value appears strong and on an upward trend. It has increased from 0.58 Cr. (Jun 2025) to 0.80 Cr., marking an increase of 0.22 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.54. The value appears strong and on an upward trend. It has increased from 0.39 (Jun 2025) to 0.54, marking an increase of 0.15.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:58 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15.61 | 19.60 | 20.09 | 27.43 | 31.45 | 55.27 | 57.45 | 53.33 | 95.27 | 95.15 | 78.47 | 70.25 | 70.69 |
| Expenses | 14.05 | 17.39 | 16.94 | 23.98 | 26.72 | 41.09 | 42.67 | 40.77 | 74.56 | 73.69 | 65.10 | 61.18 | 62.80 |
| Operating Profit | 1.56 | 2.21 | 3.15 | 3.45 | 4.73 | 14.18 | 14.78 | 12.56 | 20.71 | 21.46 | 13.37 | 9.07 | 7.89 |
| OPM % | 9.99% | 11.28% | 15.68% | 12.58% | 15.04% | 25.66% | 25.73% | 23.55% | 21.74% | 22.55% | 17.04% | 12.91% | 11.16% |
| Other Income | 0.03 | 0.06 | 0.07 | 0.31 | 0.29 | -0.30 | 0.90 | 0.84 | 1.00 | 1.05 | 1.18 | 1.53 | 2.30 |
| Interest | 0.45 | 0.42 | 0.26 | 0.35 | 0.31 | 0.28 | 0.32 | 0.15 | 0.17 | 0.82 | 0.83 | 1.64 | 2.22 |
| Depreciation | 0.50 | 0.55 | 0.50 | 0.55 | 0.67 | 1.26 | 1.18 | 1.20 | 1.59 | 2.04 | 2.29 | 3.13 | 3.74 |
| Profit before tax | 0.64 | 1.30 | 2.46 | 2.86 | 4.04 | 12.34 | 14.18 | 12.05 | 19.95 | 19.65 | 11.43 | 5.83 | 4.23 |
| Tax % | 31.25% | 34.62% | 29.27% | 47.55% | 41.58% | 24.55% | 24.96% | 25.81% | 25.51% | 26.92% | 26.16% | 28.13% | |
| Net Profit | 0.43 | 0.85 | 1.74 | 1.50 | 2.36 | 9.32 | 10.64 | 8.93 | 14.86 | 14.36 | 8.44 | 4.19 | 3.18 |
| EPS in Rs | 0.80 | 1.57 | 3.22 | 1.01 | 1.59 | 6.30 | 7.19 | 6.03 | 10.03 | 9.70 | 5.70 | 2.83 | 2.15 |
| Dividend Payout % | 0.00% | 5.29% | 2.59% | 8.23% | 5.23% | 2.65% | 18.57% | 11.06% | 19.93% | 20.63% | 17.55% | 35.35% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 97.67% | 104.71% | -13.79% | 57.33% | 294.92% | 14.16% | -16.07% | 66.41% | -3.36% | -41.23% | -50.36% |
| Change in YoY Net Profit Growth (%) | 0.00% | 7.03% | -118.50% | 71.13% | 237.58% | -280.75% | -30.23% | 82.48% | -69.77% | -37.86% | -9.13% |
Chemcrux Enterprises Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 4% |
| 3 Years: | -10% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | -17% |
| 3 Years: | -35% |
| TTM: | -52% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | -34% |
| 1 Year: | -45% |
| Return on Equity | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 17% |
| 3 Years: | 13% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 2:56 pm
Balance Sheet
Last Updated: December 4, 2025, 2:37 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.80 | 1.80 | 1.80 | 4.94 | 4.94 | 4.94 | 4.94 | 4.94 | 14.81 | 14.81 | 14.81 | 14.81 | 14.81 |
| Reserves | 4.00 | 4.76 | 6.77 | 7.54 | 9.75 | 18.92 | 27.48 | 35.92 | 39.87 | 51.60 | 57.45 | 61.30 | 62.52 |
| Borrowings | 3.46 | 2.69 | 3.61 | 4.00 | 3.73 | 2.94 | 1.92 | 0.93 | 9.11 | 14.43 | 26.46 | 26.81 | 23.73 |
| Other Liabilities | 4.53 | 4.62 | 2.96 | 4.11 | 8.37 | 11.81 | 10.20 | 6.90 | 19.32 | 12.38 | 11.15 | 9.23 | 11.66 |
| Total Liabilities | 13.79 | 13.87 | 15.14 | 20.59 | 26.79 | 38.61 | 44.54 | 48.69 | 83.11 | 93.22 | 109.87 | 112.15 | 112.72 |
| Fixed Assets | 6.94 | 7.07 | 7.54 | 8.29 | 10.75 | 11.24 | 15.40 | 19.37 | 24.32 | 33.11 | 33.09 | 57.55 | 57.04 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.21 | 0.00 | 0.00 | 0.00 | 0.32 | 0.00 | 0.31 | 21.06 | 1.61 | 3.92 |
| Investments | 0.05 | 0.05 | 0.05 | 0.05 | 1.07 | 3.89 | 6.53 | 9.35 | 7.09 | 16.79 | 19.83 | 19.84 | 16.51 |
| Other Assets | 6.80 | 6.75 | 7.55 | 12.04 | 14.97 | 23.48 | 22.61 | 19.65 | 51.70 | 43.01 | 35.89 | 33.15 | 35.25 |
| Total Assets | 13.79 | 13.87 | 15.14 | 20.59 | 26.79 | 38.61 | 44.54 | 48.69 | 83.11 | 93.22 | 109.87 | 112.15 | 112.72 |
Below is a detailed analysis of the balance sheet data for Chemcrux Enterprises Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 14.81 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.81 Cr..
- For Reserves, as of Sep 2025, the value is 62.52 Cr.. The value appears strong and on an upward trend. It has increased from 61.30 Cr. (Mar 2025) to 62.52 Cr., marking an increase of 1.22 Cr..
- For Borrowings, as of Sep 2025, the value is 23.73 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 26.81 Cr. (Mar 2025) to 23.73 Cr., marking a decrease of 3.08 Cr..
- For Other Liabilities, as of Sep 2025, the value is 11.66 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.23 Cr. (Mar 2025) to 11.66 Cr., marking an increase of 2.43 Cr..
- For Total Liabilities, as of Sep 2025, the value is 112.72 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 112.15 Cr. (Mar 2025) to 112.72 Cr., marking an increase of 0.57 Cr..
- For Fixed Assets, as of Sep 2025, the value is 57.04 Cr.. The value appears to be declining and may need further review. It has decreased from 57.55 Cr. (Mar 2025) to 57.04 Cr., marking a decrease of 0.51 Cr..
- For CWIP, as of Sep 2025, the value is 3.92 Cr.. The value appears strong and on an upward trend. It has increased from 1.61 Cr. (Mar 2025) to 3.92 Cr., marking an increase of 2.31 Cr..
- For Investments, as of Sep 2025, the value is 16.51 Cr.. The value appears to be declining and may need further review. It has decreased from 19.84 Cr. (Mar 2025) to 16.51 Cr., marking a decrease of 3.33 Cr..
- For Other Assets, as of Sep 2025, the value is 35.25 Cr.. The value appears strong and on an upward trend. It has increased from 33.15 Cr. (Mar 2025) to 35.25 Cr., marking an increase of 2.10 Cr..
- For Total Assets, as of Sep 2025, the value is 112.72 Cr.. The value appears strong and on an upward trend. It has increased from 112.15 Cr. (Mar 2025) to 112.72 Cr., marking an increase of 0.57 Cr..
Notably, the Reserves (62.52 Cr.) exceed the Borrowings (23.73 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.90 | -0.48 | -0.46 | -0.55 | 1.00 | 11.24 | 12.86 | 11.63 | 11.60 | 7.03 | -13.09 | -17.74 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 59.63 | 42.46 | 65.22 | 56.69 | 74.28 | 71.52 | 59.79 | 22.65 | 72.33 | 51.56 | 71.17 | 63.44 |
| Inventory Days | 159.97 | 104.29 | 74.71 | 105.14 | 111.70 | 71.92 | 84.82 | 137.46 | 92.33 | 124.92 | 99.63 | 127.16 |
| Days Payable | 146.63 | 73.69 | 38.26 | 54.75 | 131.52 | 75.76 | 46.42 | 15.85 | 92.57 | 71.19 | 70.84 | 52.84 |
| Cash Conversion Cycle | 72.96 | 73.06 | 101.68 | 107.07 | 54.46 | 67.67 | 98.19 | 144.26 | 72.09 | 105.28 | 99.96 | 137.76 |
| Working Capital Days | 8.18 | 8.94 | 21.80 | 34.20 | 43.17 | 47.68 | 52.48 | 67.69 | 37.51 | 67.28 | 55.49 | 50.09 |
| ROCE % | 11.87% | 18.58% | 25.85% | 22.26% | 24.81% | 58.78% | 46.03% | 31.55% | 37.64% | 27.75% | 13.46% | 7.11% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.64 | 5.70 | 9.70 |
| Diluted EPS (Rs.) | 2.64 | 5.70 | 9.70 |
| Cash EPS (Rs.) | 4.81 | 7.25 | 11.07 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 50.39 | 48.79 | 44.84 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 50.39 | 48.79 | 44.84 |
| Revenue From Operations / Share (Rs.) | 47.27 | 52.98 | 64.25 |
| PBDIT / Share (Rs.) | 7.24 | 9.82 | 15.20 |
| PBIT / Share (Rs.) | 5.07 | 8.28 | 13.82 |
| PBT / Share (Rs.) | 3.89 | 7.72 | 13.27 |
| Net Profit / Share (Rs.) | 2.64 | 5.70 | 9.70 |
| NP After MI And SOA / Share (Rs.) | 2.64 | 5.70 | 9.70 |
| PBDIT Margin (%) | 15.30 | 18.54 | 23.64 |
| PBIT Margin (%) | 10.72 | 15.62 | 21.50 |
| PBT Margin (%) | 8.22 | 14.56 | 20.64 |
| Net Profit Margin (%) | 5.58 | 10.76 | 15.08 |
| NP After MI And SOA Margin (%) | 5.58 | 10.76 | 15.08 |
| Return on Networth / Equity (%) | 5.24 | 11.68 | 21.62 |
| Return on Capital Employeed (%) | 7.01 | 12.65 | 25.13 |
| Return On Assets (%) | 3.08 | 7.68 | 14.49 |
| Long Term Debt / Equity (X) | 0.37 | 0.29 | 0.18 |
| Total Debt / Equity (X) | 0.55 | 0.35 | 0.23 |
| Asset Turnover Ratio (%) | 0.59 | 0.75 | 0.00 |
| Current Ratio (X) | 2.31 | 3.88 | 3.34 |
| Quick Ratio (X) | 1.81 | 3.23 | 2.54 |
| Inventory Turnover Ratio (X) | 7.60 | 2.25 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 37.84 | 35.07 | 20.62 |
| Dividend Payout Ratio (CP) (%) | 20.80 | 27.60 | 18.06 |
| Earning Retention Ratio (%) | 62.16 | 64.93 | 79.38 |
| Cash Earning Retention Ratio (%) | 79.20 | 72.40 | 81.94 |
| Interest Coverage Ratio (X) | 6.14 | 17.48 | 27.50 |
| Interest Coverage Ratio (Post Tax) (X) | 3.24 | 11.14 | 18.54 |
| Enterprise Value (Cr.) | 189.29 | 402.43 | 448.23 |
| EV / Net Operating Revenue (X) | 2.70 | 5.13 | 4.71 |
| EV / EBITDA (X) | 17.66 | 27.66 | 19.92 |
| MarketCap / Net Operating Revenue (X) | 2.13 | 4.87 | 4.62 |
| Retention Ratios (%) | 62.15 | 64.92 | 79.37 |
| Price / BV (X) | 2.00 | 5.29 | 6.62 |
| Price / Net Operating Revenue (X) | 2.13 | 4.87 | 4.62 |
| EarningsYield | 0.02 | 0.02 | 0.03 |
After reviewing the key financial ratios for Chemcrux Enterprises Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.64. This value is below the healthy minimum of 5. It has decreased from 5.70 (Mar 24) to 2.64, marking a decrease of 3.06.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.64. This value is below the healthy minimum of 5. It has decreased from 5.70 (Mar 24) to 2.64, marking a decrease of 3.06.
- For Cash EPS (Rs.), as of Mar 25, the value is 4.81. This value is within the healthy range. It has decreased from 7.25 (Mar 24) to 4.81, marking a decrease of 2.44.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 50.39. It has increased from 48.79 (Mar 24) to 50.39, marking an increase of 1.60.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 50.39. It has increased from 48.79 (Mar 24) to 50.39, marking an increase of 1.60.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 47.27. It has decreased from 52.98 (Mar 24) to 47.27, marking a decrease of 5.71.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 7.24. This value is within the healthy range. It has decreased from 9.82 (Mar 24) to 7.24, marking a decrease of 2.58.
- For PBIT / Share (Rs.), as of Mar 25, the value is 5.07. This value is within the healthy range. It has decreased from 8.28 (Mar 24) to 5.07, marking a decrease of 3.21.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.89. This value is within the healthy range. It has decreased from 7.72 (Mar 24) to 3.89, marking a decrease of 3.83.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.64. This value is within the healthy range. It has decreased from 5.70 (Mar 24) to 2.64, marking a decrease of 3.06.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 2.64. This value is within the healthy range. It has decreased from 5.70 (Mar 24) to 2.64, marking a decrease of 3.06.
- For PBDIT Margin (%), as of Mar 25, the value is 15.30. This value is within the healthy range. It has decreased from 18.54 (Mar 24) to 15.30, marking a decrease of 3.24.
- For PBIT Margin (%), as of Mar 25, the value is 10.72. This value is within the healthy range. It has decreased from 15.62 (Mar 24) to 10.72, marking a decrease of 4.90.
- For PBT Margin (%), as of Mar 25, the value is 8.22. This value is below the healthy minimum of 10. It has decreased from 14.56 (Mar 24) to 8.22, marking a decrease of 6.34.
- For Net Profit Margin (%), as of Mar 25, the value is 5.58. This value is within the healthy range. It has decreased from 10.76 (Mar 24) to 5.58, marking a decrease of 5.18.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 5.58. This value is below the healthy minimum of 8. It has decreased from 10.76 (Mar 24) to 5.58, marking a decrease of 5.18.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.24. This value is below the healthy minimum of 15. It has decreased from 11.68 (Mar 24) to 5.24, marking a decrease of 6.44.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.01. This value is below the healthy minimum of 10. It has decreased from 12.65 (Mar 24) to 7.01, marking a decrease of 5.64.
- For Return On Assets (%), as of Mar 25, the value is 3.08. This value is below the healthy minimum of 5. It has decreased from 7.68 (Mar 24) to 3.08, marking a decrease of 4.60.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.37. This value is within the healthy range. It has increased from 0.29 (Mar 24) to 0.37, marking an increase of 0.08.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.55. This value is within the healthy range. It has increased from 0.35 (Mar 24) to 0.55, marking an increase of 0.20.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.59. It has decreased from 0.75 (Mar 24) to 0.59, marking a decrease of 0.16.
- For Current Ratio (X), as of Mar 25, the value is 2.31. This value is within the healthy range. It has decreased from 3.88 (Mar 24) to 2.31, marking a decrease of 1.57.
- For Quick Ratio (X), as of Mar 25, the value is 1.81. This value is within the healthy range. It has decreased from 3.23 (Mar 24) to 1.81, marking a decrease of 1.42.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.60. This value is within the healthy range. It has increased from 2.25 (Mar 24) to 7.60, marking an increase of 5.35.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 37.84. This value is within the healthy range. It has increased from 35.07 (Mar 24) to 37.84, marking an increase of 2.77.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 20.80. This value is within the healthy range. It has decreased from 27.60 (Mar 24) to 20.80, marking a decrease of 6.80.
- For Earning Retention Ratio (%), as of Mar 25, the value is 62.16. This value is within the healthy range. It has decreased from 64.93 (Mar 24) to 62.16, marking a decrease of 2.77.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 79.20. This value exceeds the healthy maximum of 70. It has increased from 72.40 (Mar 24) to 79.20, marking an increase of 6.80.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 6.14. This value is within the healthy range. It has decreased from 17.48 (Mar 24) to 6.14, marking a decrease of 11.34.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.24. This value is within the healthy range. It has decreased from 11.14 (Mar 24) to 3.24, marking a decrease of 7.90.
- For Enterprise Value (Cr.), as of Mar 25, the value is 189.29. It has decreased from 402.43 (Mar 24) to 189.29, marking a decrease of 213.14.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.70. This value is within the healthy range. It has decreased from 5.13 (Mar 24) to 2.70, marking a decrease of 2.43.
- For EV / EBITDA (X), as of Mar 25, the value is 17.66. This value exceeds the healthy maximum of 15. It has decreased from 27.66 (Mar 24) to 17.66, marking a decrease of 10.00.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.13. This value is within the healthy range. It has decreased from 4.87 (Mar 24) to 2.13, marking a decrease of 2.74.
- For Retention Ratios (%), as of Mar 25, the value is 62.15. This value is within the healthy range. It has decreased from 64.92 (Mar 24) to 62.15, marking a decrease of 2.77.
- For Price / BV (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 5.29 (Mar 24) to 2.00, marking a decrease of 3.29.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.13. This value is within the healthy range. It has decreased from 4.87 (Mar 24) to 2.13, marking a decrease of 2.74.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chemcrux Enterprises Ltd:
- Net Profit Margin: 5.58%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.01% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.24% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.24
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.81
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 50.5 (Industry average Stock P/E: 67.19)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.55
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.58%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | 330, Trivia Complex, Vadodra Gujarat 390007 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Girishkumar C Shah | Executive Chairman |
| Mr. Sanjay Marathe | Managing Director |
| Mr. Vipul Sanghvi | Executive Director |
| Mr. Sidhdhi G Shah | Non Executive Director |
| Mr. Shailesh Patel | Independent Director |
| Mr. Bhanubhai Patel | Independent Director |
| Mr. Nayankumar Shah | Independent Director |
| Mr. Rohit Kothari | Independent Director |
FAQ
What is the intrinsic value of Chemcrux Enterprises Ltd?
Chemcrux Enterprises Ltd's intrinsic value (as of 05 January 2026) is ₹114.08 which is 5.63% higher the current market price of ₹108.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹161 Cr. market cap, FY2025-2026 high/low of ₹185/100, reserves of ₹62.52 Cr, and liabilities of ₹112.72 Cr.
What is the Market Cap of Chemcrux Enterprises Ltd?
The Market Cap of Chemcrux Enterprises Ltd is 161 Cr..
What is the current Stock Price of Chemcrux Enterprises Ltd as on 05 January 2026?
The current stock price of Chemcrux Enterprises Ltd as on 05 January 2026 is ₹108.
What is the High / Low of Chemcrux Enterprises Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Chemcrux Enterprises Ltd stocks is ₹185/100.
What is the Stock P/E of Chemcrux Enterprises Ltd?
The Stock P/E of Chemcrux Enterprises Ltd is 50.5.
What is the Book Value of Chemcrux Enterprises Ltd?
The Book Value of Chemcrux Enterprises Ltd is 52.2.
What is the Dividend Yield of Chemcrux Enterprises Ltd?
The Dividend Yield of Chemcrux Enterprises Ltd is 0.92 %.
What is the ROCE of Chemcrux Enterprises Ltd?
The ROCE of Chemcrux Enterprises Ltd is 7.11 %.
What is the ROE of Chemcrux Enterprises Ltd?
The ROE of Chemcrux Enterprises Ltd is 5.36 %.
What is the Face Value of Chemcrux Enterprises Ltd?
The Face Value of Chemcrux Enterprises Ltd is 10.0.